Publication: Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer
dc.contributor.coauthor | Sag, Alan A. | |
dc.contributor.coauthor | Afsar, Baris | |
dc.contributor.coauthor | Rossignol, Patrick | |
dc.contributor.coauthor | Covic, Adrian | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Çöpür, Sidar | |
dc.contributor.kuauthor | Kanbay, Mehmet | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-11-09T23:46:03Z | |
dc.date.issued | 2020 | |
dc.description.abstract | Chronic kidney disease is prevalent, affecting more than one in ten adults. In this population, metabolic acidosis is considered a key underlying pathophysiological feature, tying together bone mineral disorders, sarcopenia, insulin resistance, vascular calcification, pro-inflammatory and pro-thrombotic states. This review aims to address the paucity of literature on alkalinizing agents, a promising treatment option that has known adverse effects | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 12 | |
dc.description.openaccess | NO | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.volume | 52 | |
dc.identifier.doi | 10.1007/s11255-020-02563-2 | |
dc.identifier.eissn | 1573-2584 | |
dc.identifier.issn | 0301-1623 | |
dc.identifier.quartile | Q3 | |
dc.identifier.scopus | 2-s2.0-85087887255 | |
dc.identifier.uri | https://doi.org/10.1007/s11255-020-02563-2 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/13912 | |
dc.identifier.wos | 548170700002 | |
dc.keywords | Chronic kidney disease | |
dc.keywords | End-stage renal disease | |
dc.keywords | Metabolic acidosis | |
dc.keywords | Alkaline treatment | |
dc.keywords | Bicarbonate | |
dc.keywords | Left-ventricular hypertrophy | |
dc.keywords | Glomerular-filtration-rate | |
dc.keywords | Joint consensus statement | |
dc.keywords | Growth-factor 23 | |
dc.keywords | Insulin-resistance | |
dc.keywords | Vitamin-d | |
dc.keywords | Sodium-bicarbonate | |
dc.keywords | Phosphate binders | |
dc.keywords | Endothelial dysfunction | |
dc.keywords | Parathyroid-hormone | |
dc.language.iso | eng | |
dc.publisher | Springer | |
dc.relation.ispartof | International Urology and Nephrology | |
dc.subject | Urology | |
dc.subject | Nephrology | |
dc.title | Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer | |
dc.type | Review | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Kanbay, Mehmet | |
local.contributor.kuauthor | Çöpür, Sidar | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |